A Randomized, Double-blind, Placebo-controlled, Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Single-dose Increasing of SK-08 Tablets in Healthy Participants
Latest Information Update: 26 Jun 2025
At a glance
- Drugs SK 08 (Primary)
- Indications Renal failure
- Focus Adverse reactions
- Sponsors Consun Pharmaceutical
Most Recent Events
- 17 Jun 2025 New trial record